Soluble forms of PD-1 and sPD-L1/2 in serum and urine of patients with head and neck cancer and their clinical significance

References

• Bai, J., Bruner, D. W., Fedirko, V., Beitler, J. J., & Xiao, C. (2020). Gut microbiome associated with the psychoneurological symptom cluster in patients with head and neck cancers. Cancers, 12(9), 2531. https://doi.org/10.3390/cancers12092531
   PubMedGoogle Scholar
• Ba, Y., Ko, N., Helvac, K., Koak, C., & Ahin, H. (2021). Clinical and pathological significance of programmed cell death 1 (PD-1)/programmed cell death ligand 1 (PD-L1) expression in high grade serous ovarian cancer. Translational Oncology, 14(2), 100994. https://doi.org/10.1016/j.tranon.2020.100994
   PubMedGoogle Scholar
• Berghoff, A. S., Ricken, G., Widhalm, G., Rajky, O., Dieckmann, K., Birner, P., Preusser, M. (2015). Tumour‐infiltrating lymphocytes and expression of programmed death ligand 1 (PD‐L1) in melanoma brain metastases. Histopathology, 66(2), 289–299. https://doi.org/10.1111/his.12537
   PubMedGoogle Scholar
• Boschert, V., Teusch, J., Aljasem, A., Schmucker, P., Hartmann, S., Straub, A., Bittrich, M., Seher, A., Linz, C., Müller-Richter, U. D. A., & Hartmann, S. (2020). HGF-Induced PD-L1 expression in head and neck cancer: Preclinical and clinical findings. International Journal of Molecular Sciences, 21(22), 8770. https://doi.org/10.3390/ijms21228770
   PubMedGoogle Scholar
• Buciu Ma N, N., & Marcu, L. G. (2021). Dosimetric justification for the use of volumetric modulated arc therapy in head and neck cancer—a systematic review of the literature. Laryngoscope Investigative Otolaryngology, 6(5), 999–1007. https://doi.org/10.1002/lio2.642
   PubMedGoogle Scholar
• Cao, Y., Lu, Q., Zhuang, B., Zhang, L., & Sun, Y. (2021). The prevalence of sarcopenia and relationships between dietary intake and muscle mass in head and neck cancer patients undergoing radiotherapy: A longitudinal study. European Journal of Oncology Nursing, 53, 101943. https://doi.org/10.1016/j.ejon.2021.101943
   PubMedGoogle Scholar
• Chaker, M., Minden, A., Chen, S., Weiss, R. H., & Azmi, A. S. (2018). Rho GTPase effectors and NAD metabolism in cancer immune suppression. Expert Opinion on Therapeutic Targets, 22(1), 9–17. https://doi.org/10.1080/14728222.2018.1413091
   PubMed Web of Science ®Google Scholar
• Chatterjee, S., Maulik, S., Prasath, S., Arun, B., Das, A., Chakrabarty, S., Arunsingh, M., Nallathambi, C., Achari, R., Bhattacharya, T., & Mallick, I. (2022). Xerostomia quality of life and resource requirements following parotid sparing adaptive radiotherapy in head and neck cancers: Results of a prospective cohort study (Study ID CTRI/2017/11/010683). Radiotherapy and Oncology, 168, 250–255.
   PubMedGoogle Scholar
• Chen, J., Alduais, Y., & Chen, B. (2021). Therapeutic and systemic adverse events of immune checkpoint inhibitors targeting the PD-1/PD-L1 axis for clinical management of NSCLC. Cell Transplantation, 30(12), 1464–1472. https://doi.org/10.1177/09636897211041587
   Google Scholar
• Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., & Mego, M. (2017). Prognostic role of programmed-death ligand 1 (PD-L1) expressing tumor infiltrating lymphocytes in testicular germ cell tumors. Oncotarget, 8(13), 21794–21805. https://doi.org/10.18632/oncotarget.15585
   PubMedGoogle Scholar
• Guzik, K., Zak, K. M., Grudnik, P., Magiera, K., Musielak, B., Törner, R., Hola, T. A. (2017). Small-molecule inhibitors of the programmed cell death-1/programmed death-ligand 1 (PD-1/PD-L1) interaction via transiently induced protein states and dimerization of PD-L1. Journal of Medicinal Chemistry, 60(13), 5857–5867. https://doi.org/10.1021/acs.jmedchem.7b00293
   PubMed Web of Science ®Google Scholar
• Hsu, P. C., Wang, C. W., Kuo, C. H., Lin, S. M., Lo, Y. L., Huang, C. C., Yang, C. T. (2020). The co-expression of programmed death-ligand 1 (PD-L1) in untreated EGFR-Mutated metastatic lung adenocarcinoma. Biomedicines, 8(2), 36. https://doi.org/10.3390/biomedicines8020036
   PubMedGoogle Scholar
• Kakavand, H., Rawson, R. V., Pupo, G. M., Yang, J., & Rizos, H. (2017). PD-L1 expression and immune escape in melanoma resistance to MAPK inhibitors. Clinical Cancer Research: An Official Journal of the American Association for Cancer Research, 23(20), 6054. https://doi.org/10.1158/1078-0432.CCR-16-1688
   PubMed Web of Science ®Google Scholar
• Kasai, S., Itonaga, H., Niino, D., Miyoshi, H., & Miyazaki, Y. (2020). Correction to: Programmed death 1 ligand (PD-L1) in solid cancers after allogeneic hematopoietic stem cell transplantation: A retrospective analysis by the Nagasaki Transplant Group. International Journal of Hematology, 112(6), 906. https://doi.org/10.1007/s12185-020-03019-0
   PubMedGoogle Scholar
• Leng, C., Li, Y., Qin, J., Ma, J., Liu, X., Cui, Y., Yu, Y. (2016). Relationship between expression of PD-L1 and PD-L2 on esophageal squamous cell carcinoma and the antitumor effects of CD8+ T cells. Oncology Reports.
   Google Scholar
• Li, X., Koskinen, A. I., Hemminki, O., Frsti, A., & Hemminki, K. (2021). Family history of head and neck cancers. Cancers, 13(16), 4115. https://doi.org/10.3390/cancers13164115
   PubMedGoogle Scholar
• Lin, Y., Lin, L. Y., Hang, J. F., Lin, C. H., Ho, H. L., & Chou, T. Y. (2021). Programmed death-ligand 1 (PD-L1)/thyroid transcription factor-1 double immunohistochemical staining facilitates scoring of tumor PD-L1 expression in cytopathology specimens from lung adenocarcinoma patients. Cancer Cytopathology, 129(2), 148–155. https://doi.org/10.1002/cncy.22359
   PubMedGoogle Scholar
• Luo, M., Xia, Y., Wang, F., Zhang, H., & Fu, L. (2021). PD0325901, an ERK inhibitor, enhances the efficacy of PD-1 inhibitor in non-small cell lung carcinoma. Acta pharmaceutica Sinica B, 11(10), 3120–3133. https://doi.org/10.1016/j.apsb.2021.03.010
   PubMedGoogle Scholar
• Nisha, P., Slack, G. W., Juraj, B., Susana, B. N., Diego, V., Lisa, D., Hsi, E. D. (2022 Apr 1). Immune escape mechanisms in intravascular large B-Cell lymphoma. American Journal of Clinical Pathology 157(4), 578–585 .
   PubMedGoogle Scholar
• Pfister, D. G., Spencer, S., Adelstein, D., Adkins, D., & Darlow, S. D. (2020). Head and neck cancers, version 2.2020, NCCN clinical practice guidelines in oncology. Journal of the National Comprehensive Cancer Network: JNCCN, 18(7), 873–898. https://doi.org/10.6004/jnccn.2020.0031
   PubMed Web of Science ®Google Scholar
• Pn, A., Saba, B., Si, C., Pp, D., Lga, B., Ama, B., Kjha, B. (2020). Impact of antibiotic use during curative treatment of locally advanced head and neck cancers with chemotherapy and radiotherapy. European Journal of Cancer, 131, 9–15. https://doi.org/10.1016/j.ejca.2020.02.047
   PubMedGoogle Scholar
• Ran, X., & Kai, Y. (2017). Inhibitors of the PD-1/PD-L1 axis for the treatment of head and neck cancer: Current status and future perspectives. Drug Design Development & Therapy, 11, 2007–2014. https://doi.org/10.2147/DDDT.S140687
   PubMed Web of Science ®Google Scholar
• Sheng, Q. J., Tian, W. Y., Dou, X. G., Zhang, C., & Ding, Y. (2020). Programmed death 1, ligand 1 and 2 correlated genes and their association with mutation, immune infiltration and clinical outcomes of hepatocellular carcinoma. World Journal of Gastrointestinal Oncology, 12(11), 1255–1271. https://doi.org/10.4251/wjgo.v12.i11.1255
   PubMed Web of Science ®Google Scholar
• Silva, E., Marti, L. C., Andreghetto, F. M., Sales, R., Hoberman, M., Dias, B., Curioni, O. A. (2021 Sep 17). Extracellular vesicles cargo from head and neck cancer cell lines disrupt dendritic cells function and match plasma microRnas. Scientific Reports, 11(1), 18534.
   PubMedGoogle Scholar
• Wang, B., Cao, R., Li, P., & Fu, C. (2019). The effects and safety of PD‐1/PD‐L1 inhibitors on head and neck cancer: A systematic review and meta‐analysis. Cancer Medicine, 8(13), 5969–5978. https://doi.org/10.1002/cam4.2510
   PubMedGoogle Scholar
• Wertel, I., Kwiatkowska, A., Suszczyk, D., Chudzik, A., Tarkowski, R., Barczyński, B., Kotarski, J., & Wertel, I. (2021). Clinical and prognostic value of antigen-presenting cells with PD-L1/PD-L2 expression in ovarian cancer patients. International Journal of Molecular Sciences, 22(21), 11563. https://doi.org/10.3390/ijms222111563
   PubMedGoogle Scholar
• Yi, M., Xu, L., Jiao, Y., Luo, S., Wu, K., & Wu, K. (2020). The role of cancer-derived microRnas in cancer immune escape. Journal of Hematology & Oncology, 13(1). https://doi.org/10.1186/s13045-020-00848-8
   Google Scholar